Tirzepatide outperformed semaglutide weight-loss drug results in real world patients, study shows

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become popular for weight loss, but results vary from person to person and from drug to drug. Venky Soundararajan and colleagues explored the full range of responses to tirzepatide (e.g., Mounjaro or Zepbound) and semaglutide (e.g., Ozempic, Wegovy or Rybelsus) by analyzing de-identified electronic health records for matched cohorts of 10,339 tirzepatide-treated and 10,339 semaglutide-treated patients. In the real world, outcomes ranged from minimal weight loss to more than a 25% reduction in body weight.

Raccontata damedicalxpress.com